Tags

Type your tag names separated by a space and hit enter

Insulin resistance and polycystic ovary syndrome.
Nutr Metab Cardiovasc Dis. 2008 Sep; 18(7):511-8.NM

Abstract

Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders in humans, affecting approximately 7-8% of women of reproductive age. Despite the criteria adopted, PCOS is considered to be a predominantly hyperandrogenetic syndrome and the evaluation of metabolic parameters and insulin sensitivity is not mandatory. Most women with PCOS also exhibit features of the metabolic syndrome, including insulin resistance, obesity and dyslipidaemia. While the association with type 2 diabetes is well established, whether the incidence of cardiovascular disease is increased in women with PCOS remains unclear. Acknowledging the strong impact of insulin-resistance in the genesis of PCOS could be helpful not only to make the diagnosis more robust, but also for conferring better cardiovascular risk prevention. Several current studies support a strong recommendation that women with PCOS should undergo comprehensive evaluation for the metabolic syndrome and recognized cardiovascular risk factors, and receive appropriate treatment as needed. Lifestyle modifications remain the first-line therapy for all obese women with PCOS. However, many of these women do not lose weight easily. Insulin-sensitizing drugs are discussed as a promising and unique therapeutic option for the chronic treatment of PCOS.

Authors+Show Affiliations

Section of Endocrinology. Dipartimento di Oncologia Sperimentale e Applicazioni Cliniche, Università degli Studi Palermo, 90127 Palermo, Italy. agalluz@unipa.itNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

18657405

Citation

Galluzzo, Aldo, et al. "Insulin Resistance and Polycystic Ovary Syndrome." Nutrition, Metabolism, and Cardiovascular Diseases : NMCD, vol. 18, no. 7, 2008, pp. 511-8.
Galluzzo A, Amato MC, Giordano C. Insulin resistance and polycystic ovary syndrome. Nutr Metab Cardiovasc Dis. 2008;18(7):511-8.
Galluzzo, A., Amato, M. C., & Giordano, C. (2008). Insulin resistance and polycystic ovary syndrome. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD, 18(7), 511-8. https://doi.org/10.1016/j.numecd.2008.05.004
Galluzzo A, Amato MC, Giordano C. Insulin Resistance and Polycystic Ovary Syndrome. Nutr Metab Cardiovasc Dis. 2008;18(7):511-8. PubMed PMID: 18657405.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Insulin resistance and polycystic ovary syndrome. AU - Galluzzo,Aldo, AU - Amato,Marco Calogero, AU - Giordano,Carla, Y1 - 2008/07/25/ PY - 2008/02/19/received PY - 2008/05/22/revised PY - 2008/05/27/accepted PY - 2008/7/29/pubmed PY - 2008/10/10/medline PY - 2008/7/29/entrez SP - 511 EP - 8 JF - Nutrition, metabolism, and cardiovascular diseases : NMCD JO - Nutr Metab Cardiovasc Dis VL - 18 IS - 7 N2 - Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders in humans, affecting approximately 7-8% of women of reproductive age. Despite the criteria adopted, PCOS is considered to be a predominantly hyperandrogenetic syndrome and the evaluation of metabolic parameters and insulin sensitivity is not mandatory. Most women with PCOS also exhibit features of the metabolic syndrome, including insulin resistance, obesity and dyslipidaemia. While the association with type 2 diabetes is well established, whether the incidence of cardiovascular disease is increased in women with PCOS remains unclear. Acknowledging the strong impact of insulin-resistance in the genesis of PCOS could be helpful not only to make the diagnosis more robust, but also for conferring better cardiovascular risk prevention. Several current studies support a strong recommendation that women with PCOS should undergo comprehensive evaluation for the metabolic syndrome and recognized cardiovascular risk factors, and receive appropriate treatment as needed. Lifestyle modifications remain the first-line therapy for all obese women with PCOS. However, many of these women do not lose weight easily. Insulin-sensitizing drugs are discussed as a promising and unique therapeutic option for the chronic treatment of PCOS. SN - 1590-3729 UR - https://www.unboundmedicine.com/medline/citation/18657405/Insulin_resistance_and_polycystic_ovary_syndrome_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0939-4753(08)00112-9 DB - PRIME DP - Unbound Medicine ER -